ERBB2 and glioblastoma: To varying extents, clinical studies have evaluated CAR T cells for GBM targeting interleukin-13 receptor subunit alpha-2 (IL13Rα2), human epidermal growth factor receptor 2 (HER2) and EGFRvIII (Table 3), with follow-up studies targeting IL13Rα2 and HER2 underway.